We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Stock Moves -1.11%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Bristol-Myers Squibb (BMY - Free Report) closed at $45.37, marking a -1.11% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.32%. Elsewhere, the Dow lost 1.41%, while the tech-heavy Nasdaq lost 1.51%.
Prior to today's trading, shares of the biopharmaceutical company had lost 2.13% over the past month. This has lagged the Medical sector's loss of 1.9% and was narrower than the S&P 500's loss of 5.09% in that time.
BMY will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.03, up 1.98% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.98 billion, up 4.82% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.18 per share and revenue of $24.11 billion. These totals would mark changes of +5.03% and +6.88%, respectively, from last year.
Any recent changes to analyst estimates for BMY should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BMY is currently a Zacks Rank #1 (Strong Buy).
In terms of valuation, BMY is currently trading at a Forward P/E ratio of 10.98. This represents a discount compared to its industry's average Forward P/E of 14.36.
Meanwhile, BMY's PEG ratio is currently 2.14. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.06 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Stock Moves -1.11%: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY - Free Report) closed at $45.37, marking a -1.11% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.32%. Elsewhere, the Dow lost 1.41%, while the tech-heavy Nasdaq lost 1.51%.
Prior to today's trading, shares of the biopharmaceutical company had lost 2.13% over the past month. This has lagged the Medical sector's loss of 1.9% and was narrower than the S&P 500's loss of 5.09% in that time.
BMY will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.03, up 1.98% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.98 billion, up 4.82% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.18 per share and revenue of $24.11 billion. These totals would mark changes of +5.03% and +6.88%, respectively, from last year.
Any recent changes to analyst estimates for BMY should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BMY is currently a Zacks Rank #1 (Strong Buy).
In terms of valuation, BMY is currently trading at a Forward P/E ratio of 10.98. This represents a discount compared to its industry's average Forward P/E of 14.36.
Meanwhile, BMY's PEG ratio is currently 2.14. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.06 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.